A pilot randomized feasibility clinical trial of intranasal vs. intravenous naloxone in pediatric opioid poisoning.
Drug and Alcohol Dependence · 2026-07-03 · Randomised trial
Abstract
BACKGROUND: The opioid epidemic also affects children, yet treatment options for opioid poisoning in this population remain underexplored. This study evaluated the feasibility of a randomized trial comparing intranasal (IN) and intravenous (IV) naloxone in young children. METHODS: An open-label, randomized feasibility pilot trial was conducted at a referral hospital in Tehran from January 2021 to April 2023. Children aged 1-12 years presenting with respiratory depression, loss of consciousness, and miosis were eligible. Participants were randomized 1:1 to receive IV naloxone (0.8mg/2mL) or IN naloxone (1.26mg/0.1mL), in addition to basic first aid. The primary clinical outcome was the time from the decision to administer naloxone to the return of normal respiration. Feasibility outcomes included recruitment and retention rates, protocol adherence, acceptability, and data completeness. RESULTS: Thirty-nine children were randomized (median age 27 months). Twenty-nine had abnormal respiration, and all presented with reduced consciousness. All participants responded to naloxone, though two required an additional IV dose. Excluding an outlier, the median time to IV cannulation was 35s (IQR 26-45). The total time from decision to administration and response was 65s (IQR 49-78) in the IV group versus 24s (IQR 20-53) in the IN group. All participants adhered to the protocol, with > 90% satisfaction reported by parents and healthcare providers. CONCLUSIONS: This pilot study demonstrated that intranasal naloxone was feasible, safe, and comparable to intravenous administration for the management of opioid poisoning in young children. CLINICAL TRIAL REGISTRATION NUMBER: IRCT20120629010133N7.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antidotes · Children · Intranasal administration · Naloxone
Related articles
- American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time. (Clin Toxicol (Phila), 2023)
- Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review. (Ann Intern Med, 2017)
- The RESPONDER trial: a feasibility study of an early intervention model deploying community first responders to administer intranasal naloxone in suspected opioid overdoses in Skåne, Sweden. (BMJ Open, 2026)
- Single-step versus multi-step intranasal naloxone devices for overdose response: A randomized usability study in an at-risk population. (Am J Emerg Med, 2026)
- Efficacy of intranasal naloxone compared to other administration routes in prehospital opioid overdose management and beyond: a narrative review (Emergency Care Journal, 2025)
- Pediatric Emergency Medical Services Activations Involving Naloxone Administration. (Prehosp Emerg Care, 2025)